Experience of modern skin care series Atopic® using in atopic dermatitis children

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Atopic dermatitis - chronic allergic skin inflammatory disease with genetic predisposition, dysbalance of immune response, dysfunction of an epidermal barrier and influence of various exogenous and endogenous factors. Epidermal barrier dysfunction leads to rising of permeability of a skin for allergens, microbs and nonspecific stimuli, as well as to sensitivity to various external influences. Clinically these implications are shown by skin xerosis symptoms therefore. According to modern clinical guidelines, the moisturizing agents, so called emollients, have to be used at all disease stages. Own data on use of modern skin care series Atopic® in complex therapy of atopic dermatitis patients are presented in the article.

Full Text

Restricted Access

About the authors

O G Elisyutina

Institute of Immunology

Email: el-olga@yandex.ru

A O Litovkina

Institute of Immunology

E S Fedenko

Institute of Immunology


  1. Хаитов Р.М., Ильина Н.И. Аллергология. Федеральные клинические рекомендации. М., «Фармарус Принт Медиа». 2014, 124 с.
  2. Bouwstra J.A., Pilgrim K., Ponec M. Structure of the skin barrier, in Skin barrier, edited by P.M. Elias, K.R. Feingold. New York, Naylor and Francis. 2006, 65 p.
  3. Kezic S., Novak N., Jakasa I. et al. Skin barrier in atopic dermatitis. Front Biosci. 2014, v. 1, p. 542-556.
  4. Гущин И.С. Эпидермальный барьер и аллергия. Рос. Аллергол. Журн. 2007, № 2, с. 3-16.
  5. Irvine A.D., McLean W.H., Leung D.Y Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 2011, v. 365, p. 1315-1327.
  6. Baek J.H., Lee S.E., Choi K.J. et al. Acute modulations in stratum corneum permeability barrier function affect claudin expression and epidermal tight junction function via changes of epidermal calcium gradient. Yonsey Med. J. 2013, v. 54, p. 523-528.
  7. Elias P.M., Eichenfield L.F., Fowler J.F. Jr. et al. Update on the structure and function of the skin barrier: atopic dermatitis as an exemplar of clinical implications. Semin. Cutan. Med. Surg. 2013, v. 32, p. 21-24.
  8. Lee S.E., Jeong S.K., Lee S.H. Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med. J. 2010, v. 51, p. 808-822.
  9. Adachi Y., Hatano Y., Sakai T., Fujiwara S. Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PRAPalpha modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes. Exp. Dermatol. 2013, v. 22, p. 606-608.
  10. Afshar M., Gallo R.L. Innate immune defense system of the skin. Vet. Dermatol. 2013, v. 24, p. 32-38.
  11. Janssens M., van Smeden J., Gooris G.S. et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients J. Lipid. Res. 2012, v. 53, p. 2755-2766.
  12. Di Nardo A., Wertz P., Giannetti A., Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm. Venereol. 1998, v. 78, p. 27-30.
  13. Breternitz M., Kowatzki D., Langenauer M. et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin. Pharmacol. Physiol. 2008, v. 21, p. 39-45.
  14. Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1045-1060.
  15. Eichenfield L.F., Tom W.L., Berger T.G. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J. Am. Acad. Dermatol. 2014, v. 71, p. 116-132.
  16. Simpson E. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J. Dermatol. Treat. 2013, v. 24, p. 122-125.
  17. Korting H.C., Schollmann C., Cholcha W. et al. Efficacy and tolerability of pale sulfonated shale oil cream 4% in the treatment of mild to moderate atopic eczema in children: a multicentre, randomized vehicle-controlled trial. J. Eur. Acad. Dermatol. Venereol. 2010, v. 24, p. 1176-1182.
  18. Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007, v. 214, p. 61-67.
  19. Msika P., De Belilovsky C., Piccardi N. et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr. Dermatol. 2008, v. 25, p. 606-612.
  20. Kownacki S. The importance of emollients in treating the increasing incidence of atopic eczema. Nurs. Times. 2009, v. 105 (28), p. 18-22.
  21. Тлиш М.М., Глузмин М.И., Карташевская М.И., Псавок Ф.А. Атопический дерматит у детей: перспективы применения инновационных средств в наружной терапии. Вестник дерматологии и венерологии. 2016, № 2, с. 96-102.
  22. Stadler J.F., Taieb A. Severity scoring ofatopic dermatitis: the SCORAD index. Consensus report ofthe European task force on atopic dermatitis. Dermatology. 1993, v. 186, p. 23-31.

Copyright © Pharmarus Print Media, 2017

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies